Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) on Monday, soared 7.21% from the previous trading day, before settling in for the closing price of $0.06. Within the past 52 weeks, ADAP’s price has moved between $0.05 and $1.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 26.53% over the last five years. The company achieved an average annual earnings per share of -66.67%. With a float of $255.41 million, this company’s outstanding shares have now reached $265.05 million.
The firm has a total of 506 workers. Let’s measure their productivity.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Adaptimmune Therapeutics Plc ADR is 3.64%, while institutional ownership is 27.56%. The most recent insider transaction that took place on Aug 18 ’25, was worth 176,062. In this transaction Director of this company sold 14,671,794 shares at a rate of $0.01, taking the stock ownership to the 0 shares. Before that another transaction happened on Aug 15 ’25, when Company’s Director sold 4,828,206 for $0.01, making the entire transaction worth $53,110. This insider now owns 14,671,794 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.01 earnings per share (EPS) for the period topping the consensus outlook (set at -0.18) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -66.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -6.27% during the next five years compared to 26.53% growth over the previous five years of trading.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Adaptimmune Therapeutics Plc ADR (ADAP) is currently performing well based on its current performance indicators. A quick ratio of 1.29 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.16 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Analysing the last 5-days average volume posted by the [Adaptimmune Therapeutics Plc ADR, ADAP], we can find that recorded value of 31.07 million was better than the volume posted last year of 12.38 million. As of the previous 9 days, the stock’s Stochastic %D was 18.68%.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 2.94%, which indicates a significant decrease from 23.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0097 in the past 14 days, which was lower than the 0.0221 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1858, while its 200-day Moving Average is $0.4000. Now, the first resistance to watch is $0.0636. This is followed by the second major resistance level at $0.0661. The third major resistance level sits at $0.0704. If the price goes on to break the first support level at $0.0568, it is likely to go to the next support level at $0.0525. Should the price break the second support level, the third support level stands at $0.0500.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
Market capitalization of the company is 16.17 million based on 265,052K outstanding shares. Right now, sales total 178,030 K and income totals -70,810 K. The company made 13,680 K in profit during its latest quarter, and -30,340 K in sales during its previous quarter.
